Sanid. mil. 2021; 77 (1) 33
Evaluación positiva de medicamentos: octubre 2020
la transcriptasa inversa no análogos de los nucleósidos (ITINN) e
inhibidores de la integrasa (INI)».
El uso de esta combinación, como ya se explicó anteriormente
permite reducir la frecuencia de administración a una
vez al mes o una vez cada dos meses en comparación con la
administración oral diaria. Rekambys® estará disponible como
suspensión inyectable de liberación prolongada (600 y 900 mg)
y ser prescrito por médicos con experiencia en el manejo de la
infección por VIH.
Los datos de eficacia y seguridad son los ya descritos en el
apartado dedicado a cabotegravir (Vocabria®) al inicio de esta
revisión.
BIBLIOGRAFÍA
1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Boletín
mensual de la AEMPS sobre medicamentos de uso humano del mes
de octubre de 2020. Disponible en: https://www.aemps.gob.es/informa/boletines
aemps/boletinMensual/2020-3/boletin-mensual-de-la-aemps-sobremedicamentos
de-uso-humano-del-mes-de-octubre-de-2020/#nuevosMed.
2. European Medicines Agency. EPAR-Product Information of Vocabria®.
Consultado el 25/02/2021.Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/vocabria-epar-public-assessment-report_en.pdf.
3. Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton
ET, Girard PM, et al. Long-Acting Cabotegravir and Rilpivirine after
Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19; 382(12):
1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. PMID:
32130806.
4. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten
A, Masiá M, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance
of HIV-1 Suppression. N Engl J Med. 2020 Mar 19; 382(12): 1112-
1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4. PMID: 32130809.
5. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y,
Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine
in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised,
open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23; 390(10101):
1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24. PMID:
28750935.
6. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected
men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled,
phase 2a trial. Lancet HIV. 2017 Aug; 4(8): e331-e340. doi: 10.1016/
S2352-3018(17)30068-1. Epub 2017 May 22. PMID: 28546090.
7. European Medicines Agency. EPAR-Product Information of Tecartus®.
Consultado el 28/02/2021.Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/tecartus-epar-public-assessment-report_en.pdf.
8. European Medicines Agency. Orphan Maintenance Assessment Report- Tecartus
®. Consultado el 25/02/2021.Disponible en:https://www.ema.europa.
eu/en/documents/orphan-maintenance-report/tecartus-orphan-maintenance
assessment-report_en.pdf.
9. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19
CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N
Engl J Med. 2020 Apr 2; 382(14): 1331-1342. doi: 10.1056/NEJMoa1914347.
PMID: 32242358; PMCID: PMC7731441.
10. European Medicines Agency. EPAR-Product Information of Libmeldy®.
Consultado el 01/03/2021.Disponible en: https://www.ema.europa.eu/en/documents/
product-information/libmeldy-epar-product-information_en.pdf.
11. European Medicines Agency. Orphan Maintenance Assessment Report- Libmeldy
®. Consultado el 01/03/2021.Disponible en:https://www.ema.europa.
eu/en/documents/orphan-maintenance-report/libmeldy-orphan-maintenance
assessment-report_en.pdf.
12. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral
hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.
Science. 2013 Aug 23; 341(6148): 1233158. doi: 10.1126/science.1233158.
Epub 2013 Jul 11. PMID: 23845948.
13. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, et al.
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic
leukodystrophy: an ad-hoc analysis of a non-randomised, open-label,
phase 1/2 trial. Lancet. 2016 Jul 30; 388(10043): 476-87. doi: 10.1016/S0140-
6736(16)30374-9. Epub 2016 Jun 8. PMID: 27289174.
14. European Medicines Agency. EPAR-Public Assessment Report - Fintepla®.
Consultado el 05/03/2021.Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/fintepla-epar-public-assessment-report_en.pdf.
15. European Medicines Agency. Orphan Maintenance Assessment Report- Fintepla
®. Consultado el 05/03/2021. Disponible en: https://www.ema.europa.
eu/en/documents/assessment-report/fintepla-epar-public-assessment-report_
en.pdf.
16. Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine
hydrochloride for the treatment of seizures in Dravet syndrome:
a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;
394(10216): 2243-2254. doi: 10.1016/S0140-6736(19)32500-0. Epub 2019
Dec 17. PMID: 31862249.
17. Pierce JG, Mithal DS. Fenfluramine: New Treatment for Seizures in Dravet
Syndrome. Pediatr Neurol Briefs. 2020 Mar 12; 34: 8. doi: 10.15844/pedneurbriefs
34-8. PMID: 32189958; PMCID: PMC7071945.
18. Schoonjans A, Paelinck BP, Marchau F, Gunning B, Gammaitoni A, et al.
Low-dose fenfluramine significantly reduces seizure frequency in Dravet
syndrome: a prospective study of a new cohort of patients. Eur J Neurol.
2017 Feb; 24(2): 309-314. doi: 10.1111/ene.13195. Epub 2016 Oct 28. PMID:
27790834; PMCID: PMC5298030.
19. Sharawat IK, Panda PK, Kasinathan A, Panda P, Dawman L, Joshi K. Efficacy
and tolerability of fenfluramine in patients with Dravet syndrome: A
systematic review and meta-analysis. Seizure. 2021 Feb; 85: 119-126. doi:
10.1016/j.seizure.2020.12.016. Epub 2021 Jan 11. PMID: 33461030.
20. European Medicines Agency. EPAR-Public assesment report of Trixeo
Aerosphere®. Consultado el 06/03/2021. Disponible en: https://www.ema.
europa.eu/en/documents/assessment-report/trixeo-aerosphere-epar-publicassessment
report_en.pdf.
21. European Medicines Agency. EPAR-Risk-Management-Plan Summary of
Trixeo Aerosphere®. Consultado el 06/03/2021. Disponible en: https://www.
ema.europa.eu/en/documents/rmp-summary/trixeo-aerosphere-epar-riskmanagement
plan-summary_en.pdf.
22. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et
al. A phase III study of triple therapy with budesonide/glycopyrrolate/
formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg
using co-suspension delivery technology in moderate-to-very severe COPD:
The ETHOS study protocol Respir Med. 2019 Oct-Nov; 158: 59-66. doi:
10.1016/j.rmed.2019.08.010. Epub 2019 Aug 22. PMID: 31605923.
23. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M,
et al. Triple Therapy with budesonide/glycopyrrolate/formoterol fumarate
with co-suspension delivery technology versus dual therapies in chronic
obstructive pulmonary disease (KRONOS): a double-blind, parallel-group,
multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018
Oct;6(10):747-758. doi:10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16.
Erratum in: Lancet Respir Med. 2018 Oct 4; Erratum in: Lancet Respir Med.
2019 Feb;7(2):e9. PMID: 30232048.
24. European Medicines Agency. EPAR- Public assesment report of Leqvio®.
Consultado el 03/03/2021. Disponible en: https://www.ema.europa.eu/en/
documents/assessment-report/leqvio-epar-public-assessment-report_en.pdf.
25. European Medicines Agency. EPAR-Risk-Management-Plan Summary of
Leqvio®. Consultado el 03/03/2021. Disponible en: https://www.ema.europa.
eu/en/documents/rmp-summary/leqvio-epar-risk-management-plan-summary_
en.pdf.
26. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two
Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N
Engl J Med. 2020 Apr 16; 382(16): 1507-1519. doi:10.1056/NEJMoa1912387.
Epub 2020 Mar 18. PMID: 32187462.
27. European Medicines Agency. EPAR-Public assesment report of Oxlumo®.
Consultado el 03/03/2021Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/oxlumo-epar-public-assessment-report_en.pdf.
28. European Medicines Agency. EPAR-Risk-Management-Plan Summary of
Oxlumo®. Consultado el 03/03/2021.Disponible en: https://www.ema.europa.
eu/en/documents/rmp-summary/oxlumo-epar-risk-management-plan-summary_
en.pdf.